论文部分内容阅读
目的:探讨微生态制剂在儿科临床的应用情况。方法:随机抽取300例门诊患儿的处方,分析其中微生态制剂的应用情况。结果:有24例使用微生态制剂,占处方总数的8%,其中酪酸梭菌肠球菌三联活菌片(适怡)使用率最高,占45.83%(11例)。主要用于治疗呼吸道疾病(7例)、消化系统疾病(10例)、呼吸道疾病合并消化系统疾病(5例)和保健(2例)。微生态制剂与抗生素联用率为41.66%(10例);与消化系统用药联用率为16.67%(4例);无2种或2种以上微生态制剂合用。微生态制剂应用中95.83%(23例)为合理用药;4.17%(1例)为不合理用药(无明显用药指征)。结论:我院儿科微生态制剂的临床应用基本合理。
Objective: To investigate the clinical application of probiotics in pediatrics. Methods: A total of 300 outpatients were selected randomly to analyze the application of probiotics. Results: There were 24 cases using probiotics, accounting for 8% of the total number of prescriptions. Among which, Clostridium butyricum Enterococci triple (41.83%) had the highest utilization rate (45.83%). Mainly for the treatment of respiratory diseases (7 cases), digestive diseases (10 cases), respiratory diseases with digestive diseases (5 cases) and health care (2 cases). The combination rate of probiotics and antibiotics was 41.66% (10 cases). The combination rate with the digestive system was 16.67% (4 cases). No two or more than two kinds of probiotics were used together. 95.83% (23 cases) of probiotics were used rationally; 4.17% (1 case) were irrational drugs (no obvious indications for drug use). Conclusion: The clinical application of pediatric probiotics in our hospital is reasonable.